Transgene announces the receipt of $15.3 million (€14 million) from the sale of its entire minority stake in a Chinese biopharmaceutical company, a financial asset that had been earmarked for sale.

Following this transaction, which was expected to be completed by mid-2023, the biotech company (specializing in viral immunotherapies for the treatment of cancer) confirms financial visibility until early 2024.

We anticipate refinancing before the end of the year, in order to extend financial visibility beyond early 2024 and enable the company to pursue its development in line with its strategic plan", commented Invest Securities.

Copyright (c) 2023 CercleFinance.com. All rights reserved.